Trust Signals
Written by the FormBlends Medical Team. Reviewed against published Phase 2 trial data (Jastreboff et al., NEJM 2023), FDA drug approval records, and ClinicalTrials.gov registry entries. No financial relationship with Eli Lilly or any peptide vendor. Last reviewed May 29, 2026.
Key Takeaways
- Retatrutide produced a mean 24.2% body weight loss at 12 mg over 48 weeks in Phase 2 (n=338), the highest ever published for an incretin agent at the time of publication.
- As of May 2026, retatrutide (LY3437943) has no FDA approval; it cannot be legally prescribed, compounded, or dispensed in the United States.
- The only lawful access route in the US is enrollment in an active Eli Lilly Phase 3 clinical trial via ClinicalTrials.gov.
- Grey-market "retatrutide peptide" products carry zero regulatory oversight; vendor COAs confirm partial chemical identity but do not confirm sterility, endotoxin level, or correct tertiary structure.
- Retatrutide activates three receptors (GLP-1, GIP, glucagon), which separates it mechanistically from all currently approved weight-loss drugs and introduces a glucagon-related heart rate risk not seen with semaglutide.
Direct Answer: What Is Retatrutide Peptide and Can You Get It Near You?
Retatrutide is an investigational triple incretin receptor agonist developed by Eli Lilly, currently in Phase 3 trials. It is not FDA approved. No pharmacy, clinic, or medspa can legally supply it in the United States. If you search "retatrutide peptide near me," any result that offers a product is selling an unregulated research chemical, not a pharmaceutical.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What exactly is retatrutide and how does it work?
- What does the clinical evidence actually show?
- Evidence ledger: grading the major claims
- What is the legal status of retatrutide in the US?
- Where can you actually get retatrutide near you right now?
- What most pages get wrong about grey-market retatrutide
- What are the real risks and side effects?
- Honest head-to-head: retatrutide vs. approved alternatives
- Operational label literacy: how to read a peptide vendor COA
- FAQ
- Sources
What Exactly Is Retatrutide and How Does It Work?
Retatrutide (LY3437943) is a once-weekly injectable peptide that acts as a full agonist at three incretin-related receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This tri-agonism is the core mechanistic claim. Each receptor contributes a distinct action.
- GLP-1 receptor agonism: Slows gastric emptying, suppresses appetite via hypothalamic pathways, and stimulates glucose-dependent insulin release. This is the same pathway targeted by semaglutide.
- GIP receptor agonism: Believed to enhance insulin secretion synergistically and may reduce nausea associated with GLP-1 agonism alone. This is also targeted by tirzepatide.
- Glucagon receptor agonism: Increases hepatic glucose output and, critically, raises resting energy expenditure and promotes hepatic fat oxidation. This is the mechanism no currently approved agent shares at meaningful potency. It is also the mechanism responsible for retatrutide's greater heart rate effect.
The glucagon component is what makes retatrutide theoretically superior for fat mass and hepatic steatosis reduction. It is also the mechanism that introduces the most uncertainty, because glucagon agonism at higher doses increases heart rate and may stress cardiovascular function in susceptible individuals. The Phase 2 trial observed mean heart rate increases of roughly 4 to 5 beats per minute at higher doses, compared to roughly 1 to 2 bpm for semaglutide in published STEP data. Exact figures vary by dose arm; readers should consult Jastreboff et al. 2023 supplementary data for dose-specific tables.
What Does the Clinical Evidence Actually Show?
The pivotal published data come from one Phase 2 randomized controlled trial: Jastreboff AM et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity," New England Journal of Medicine, 2023. Key specifics:
- Sample size: 338 adults with obesity (BMI 30 or higher) or overweight with at least one comorbidity
- Duration: 48 weeks of treatment, 5-week follow-up
- Doses tested: 1 mg, 4 mg, 8 mg, 12 mg (with slow escalation) vs. placebo
- Primary endpoint: percent change in body weight at week 48
- Result at 12 mg: mean body weight reduction of 24.2% vs. 2.1% for placebo
- Result at 8 mg: mean reduction of approximately 22.8%
Phase 3 trials (the TRIUMPH program) were enrolling as of mid-2025 and results had not been published as of this writing. Phase 2 data are promising but the sample size is small relative to Phase 3 programs for approved drugs, and the trial was not powered to detect cardiovascular outcomes.
Evidence Ledger: Grading the Major Claims
| Claim | Best Evidence Type | Effect Direction | Confidence | Key Caveat |
|---|---|---|---|---|
| ~24% weight loss at 48 weeks (12 mg) | Phase 2 RCT, n=338 (Jastreboff 2023) | Strong positive | Moderate | Phase 2 only; Phase 3 replication unconfirmed as of this writing |
| GLP-1/GIP/glucagon tri-agonism mechanism | Receptor binding assays, published pharmacology | Established mechanism | High (mechanism); Moderate (clinical consequence) | Mechanism does not guarantee net clinical superiority in all populations |
| Reduction in hepatic fat | Phase 2 MRI substudies (Jastreboff 2023 supplementary) | Positive | Moderate | Small subsample; not a primary endpoint |
| Cardiovascular outcomes benefit | No cardiovascular outcome trial published | Unknown | Very Low | Heart rate increase is a concern; CVOT data absent |
| Grey-market products match clinical-grade retatrutide | No published third-party verification | Cannot be assumed | Very Low | No regulatory oversight; COA covers purity, not full characterization |
What Is the Legal Status of Retatrutide in the US?
Retatrutide is an investigational new drug (IND) under Eli Lilly's exclusive development. As of May 2026, it holds no FDA approval under any New Drug Application. It is not on the FDA 503A or 503B compounding shortage list. This means:
- Physicians cannot prescribe it
- Licensed compounding pharmacies cannot legally prepare it
- Medspas and wellness clinics cannot legally administer it
- Importation for personal use does not carry a formal legal exemption for unapproved drugs of this type
Any commercial entity advertising "retatrutide near me" or selling it as a compounded product is operating outside US law as currently written. The FDA has taken enforcement action against peptide vendors in recent years; the regulatory environment has tightened, not loosened.
Where Can You Actually Get Retatrutide Near You Right Now?
The single lawful answer is clinical trial enrollment. Search ClinicalTrials.gov using the term "retatrutide" or the identifier LY3437943. The TRIUMPH Phase 3 program includes trials for obesity, type 2 diabetes, and related conditions conducted at academic medical centers and research sites across the US. Enrollment requires eligibility screening. Participants receive the drug, monitoring, and associated care at no cost, which is a substantial practical benefit over grey-market self-administration.
If Phase 3 results are positive and an NDA is submitted and approved, commercial availability through standard pharmacy channels would follow. A conservative estimate for that scenario, if data are favorable, is sometime in 2026 to 2027, but this remains speculative and depends entirely on trial outcomes and regulatory timelines.
What Most Pages Get Wrong About Grey-Market Retatrutide
The COA problem: Peptide vendors routinely provide certificates of analysis showing HPLC purity (often listed as 98% or above) and mass spectrometry confirming molecular weight. This is the information most buyers treat as sufficient. It is not. Here is what a typical vendor COA does NOT confirm:
- Sterility: Injectable peptides require USP sterility testing. Grey-market products are rarely manufactured in ISO-classified cleanrooms. Bacterial or fungal contamination in an injectable is a direct patient safety hazard.
- Endotoxin level: Bacterial endotoxins (pyrogens) can be present even in a sterile-filtered product that passes purity testing. Endotoxin testing (LAL test) is a separate assay that most vendor COAs omit entirely.
- Correct tertiary structure and folding: Mass spec confirms the peptide has the right molecular weight, but not that it is correctly folded into an active conformation. A misfolded peptide may appear pure by HPLC and correct by mass spec while being biologically inactive or unpredictably immunogenic.
- Correct sequence relative to LY3437943: Eli Lilly's proprietary sequence and fatty acid conjugate (which determines the long half-life enabling once-weekly dosing) are not publicly disclosed at the level of detail needed to confirm a copy. A vendor cannot prove their product matches the clinical candidate without access to that proprietary data.
What Are the Real Risks and Side Effects?
The Phase 2 trial (Jastreboff et al., NEJM 2023) reported the following adverse events at higher doses:
- Nausea, vomiting, diarrhea, and constipation were the most common adverse events, affecting a majority of participants in the higher dose arms, predominantly during dose escalation phases
- Most gastrointestinal events were mild to moderate in severity
- Elevated heart rate: mean increases of approximately 4 to 5 bpm at higher doses, a signal not typically seen with GLP-1 agents alone and attributable to the glucagon receptor component
- Two cases of gallbladder-related events, consistent with the known GLP-1 drug class effect
- No cases of pancreatitis were reported in Phase 2, though this remains a class-level concern that Phase 3 data and post-approval surveillance would be needed to characterize fully
The elevated heart rate signal is particularly important for individuals with pre-existing cardiac conditions. Approved GLP-1 agents show neutral or favorable cardiovascular outcome data partly because they do not significantly raise heart rate. Retatrutide's glucagon agonism introduces a theoretical cardiovascular concern that has not been resolved by a dedicated cardiovascular outcome trial as of this writing.
Honest Head-to-Head: Retatrutide vs. Approved Alternatives
| Feature | Retatrutide (investigational) | Tirzepatide (Zepbound, approved) | Semaglutide 2.4 mg (Wegovy, approved) |
|---|---|---|---|
| Mechanism | GLP-1 + GIP + glucagon tri-agonist | GLP-1 + GIP dual agonist | GLP-1 agonist |
| Best published weight loss (RCT) | 24.2% at 48 wk (Phase 2, n=338) | ~22.5% at 72 wk (SURMOUNT-1, n=2,539) | ~15% at 68 wk (STEP-1, n=1,961) |
| FDA approval status | No (investigational) | Yes (obesity, 2023) | Yes (obesity, 2021) |
| Legal availability | Clinical trial only | Prescription, standard pharmacy | Prescription, standard pharmacy |
| Cardiovascular outcome trial | None published | SURMOUNT-MMO ongoing; partial data positive | SELECT trial: 20% MACE reduction (2023) |
| Heart rate effect | Moderate increase (~4-5 bpm at high doses) | Small increase (~2-4 bpm) | Small increase (~1-2 bpm) |
| Long-term safety data | Absent (Phase 2 only) | Growing (Phase 3 plus post-approval) | Extensive (years of post-approval data) |
| Where retatrutide wins | Greater mean weight loss in Phase 2; potentially superior hepatic fat reduction; once-weekly long half-life design | ||
| Where retatrutide loses (currently) | No legal access, no cardiovascular safety data, greater heart rate risk, no post-approval pharmacovigilance system | ||
Operational Label Literacy: How to Read a Peptide Vendor COA
If someone presents you with a COA for a retatrutide product, use this checklist to understand what it does and does not tell you:
| COA Field | What It Means | What It Does NOT Confirm |
|---|---|---|
| HPLC purity (e.g., 98.5%) | That fraction of the measured sample elutes at the expected retention time | Identity of impurities, biological activity, folding state |
| Mass spec (molecular weight match) | The molecular weight of the dominant peak matches the expected value | Amino acid sequence, post-translational modifications, fatty acid conjugate structure |
| Sterility test (if present) | Sample passed a compendial sterility assay in the tested lot | That your specific vial is sterile; lot-to-lot consistency |
| Endotoxin / LAL test (if present) | Endotoxin below stated limit in tested sample | Pyrogen-free status for every vial; test method validation |
| Sequence confirmation (if claimed) | Vendor's stated sequence was verified (usually by mass spec fragmentation) | That the sequence matches Eli Lilly's proprietary LY3437943 precisely |
Reconstitution note for research use: Lyophilized peptides of this type are typically reconstituted in bacteriostatic water. Use the labeled weight (in milligrams) and the desired concentration (in mg/mL) to calculate volume. For example, 5 mg peptide plus 2.5 mL bacteriostatic water yields 2 mg/mL. Store reconstituted product refrigerated (2 to 8 degrees Celsius) and use within the vendor's stated window, usually 4 weeks, after which oxidation and hydrolysis progressively degrade activity. A degraded product typically shows no visible change and cannot be detected by appearance alone.
FAQ
Is retatrutide FDA approved?
No. As of May 2026, retatrutide (LY3437943) is an investigational compound in Phase 3 clinical trials by Eli Lilly. It holds no FDA approval for any indication and cannot be legally prescribed or dispensed in the United States.
What is retatrutide and how does it work?
Retatrutide is a triple incretin receptor agonist that simultaneously activates GIP, GLP-1, and glucagon receptors. This tri-agonism is designed to reduce appetite via GLP-1, improve lipid metabolism and energy expenditure via GIP and glucagon pathways, and lower hepatic fat.
What weight loss results did retatrutide show in trials?
In the Jastreboff et al. Phase 2 trial (NEJM, 2023, n=338), participants on the 12 mg dose lost a mean of 24.2% body weight over 48 weeks versus 2.1% for placebo. This is the highest percentage weight loss reported in any published incretin trial at the time of publication.
Can compounding pharmacies legally make retatrutide?
No. Because retatrutide is not FDA approved and is not on the FDA 503A or 503B shortage list, licensed compounding pharmacies cannot legally compound it. Any compounded retatrutide sold in the US exists outside lawful pharmaceutical channels.
Where can I find retatrutide near me?
There is no legal retail, pharmacy, or clinic source for retatrutide in the US as of May 2026. Products marketed as retatrutide are research chemical or grey-market peptides with no guaranteed identity, purity, or sterility. Clinical trial enrollment via ClinicalTrials.gov is the only lawful access route.
What are the risks of buying retatrutide from an online peptide vendor?
Grey-market peptide products carry risks including incorrect amino acid sequence, underdosing or overdosing, microbial contamination from non-sterile manufacturing, and unknown long-term safety. There is no regulatory oversight, no product recall system, and no liability if harm occurs.
How does retatrutide compare to tirzepatide or semaglutide?
In Phase 2 data, retatrutide produced greater mean body weight reduction (24.2% at 12 mg, 48 weeks) than tirzepatide's Phase 3 peak (roughly 22.5%, SURMOUNT-1) or semaglutide 2.4 mg (roughly 15%, STEP-1). Head-to-head RCTs have not been conducted.
What are the main side effects of retatrutide?
In the Phase 2 trial, nausea, vomiting, diarrhea, and constipation were the most common adverse events, affecting a majority of participants at higher doses. Most were mild to moderate and occurred during dose escalation. Heart rate increases were also noted at higher doses.
How do I enroll in a retatrutide clinical trial?
Search ClinicalTrials.gov for "retatrutide" or "LY3437943" to find active Phase 3 trials. Trials are conducted at major academic medical centers and require eligibility screening. Enrollment is the only lawful way to access retatrutide in the US today.
What does a COA for a peptide research product actually tell you?
A certificate of analysis from a grey-market vendor typically shows HPLC purity and mass spec identity. It does not confirm sterility, correct folding, endotoxin levels, or that the product matches the exact Eli Lilly proprietary sequence. Treat any vendor COA as partial reassurance, not full safety clearance.
Is retatrutide the same as a GLP-1 agonist?
Retatrutide activates GLP-1 receptors but is not solely a GLP-1 agonist. It also activates GIP and glucagon receptors, making it a triple agonist. The glucagon component in particular distinguishes it from approved GLP-1 and dual GIP/GLP-1 agents.
When might retatrutide receive FDA approval?
Eli Lilly's Phase 3 program (TRIUMPH trials) was ongoing as of mid-2025 and results had not been published as of this writing. If Phase 3 results are positive and an NDA is submitted, regulatory review typically takes 12 months or more. A realistic FDA approval window, if data are favorable, is 2026 to 2027, though this is speculative.
Sources
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Frías JP, Deenadayalan S, Erichsen L, et al. Retatrutide Phase 2 results in type 2 diabetes. New England Journal of Medicine. 2023;389(6):527-540. doi:10.1056/NEJMoa2302029
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine. 2021;384(11):989-1002.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232.
- US Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov. Accessed May 2026.
- ClinicalTrials.gov. Search: LY3437943 (retatrutide). National Library of Medicine. clinicaltrials.gov. Accessed May 2026.
- US Pharmacopeia. USP General Chapter 71: Sterility Tests. United States Pharmacopeia and National Formulary. Rockville, MD.
- US Pharmacopeia. USP General Chapter 85: Bacterial Endotoxins Test. United States Pharmacopeia and National Formulary. Rockville, MD.
Footer Disclaimers
Platform: FormBlends is an informational and educational platform. Nothing on this page constitutes medical advice, diagnosis, or treatment recommendation. Consult a licensed healthcare provider before making any medical decision.
Research Compound: Retatrutide is an investigational compound. It is not approved by the FDA or any major regulatory agency for commercial use as of the date of this publication. References to research use are for educational context only.
Results: Weight loss percentages cited are mean values from specific clinical trial populations under controlled conditions with medical supervision and dose escalation protocols. Individual results in any setting would vary substantially and cannot be predicted.
Trademark: LY3437943 and retatrutide are associated with Eli Lilly and Company. Zepbound is a registered trademark of Eli Lilly and Company. Wegovy is a registered trademark of Novo Nordisk A/S. FormBlends has no affiliation with either company.